Viromed Medical AG signs letter of intent to acquire relyon plasma GmbH

About this update from Viromed Medical Ag

EQS-Ad-hoc: Viromed Medical AG / Key word(s): Mergers and Acquisitions / Purchase of parts of a company Viromed Medical AG signs letter of intent to acquire relyon plasma GmbH 03-March-2026 / 17:45 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group . The issuer is solely responsible for the content of this announcement. Viromed Medical AG signs letter of intent to acquire relyon plasma GmbH Rellingen, March 03, 2026 – Viromed Medical AG ("Viromed“; ISIN: DE000A40ZVN7), a medical technology company and pioneer in cold plasma technology, has today signed a letter of intent to acquire all shares in relyon plasma GmbH, which is based in Regensburg (“relyon”). The purchase price is currently under negotiation, but Viromed estimates it will be in the low- to mid-double-digit million euro range. The conclusion of the corresponding share purchase agreement is expected to be concluded in the second quarter of 2026 and will be subject to a successful due diligence review and the fulfilment of customary closing conditions. relyon is a subsidiary of TDK Electronics AG and is one of the leading technology providers in the field of atmospheric plasma technology. reylon develops modular systems and customized OEM components for industrial and medical applications and has an extensive international patent portfolio in the field of plasma technology. In recent years, Viromed has worked with relyon to develop the cold plasma medical devices in the ViroCAP® and PulmoPlas® product families. In addition, relyon is currently handling the production of these systems on behalf of Viromed. Through this planned acquisition, Viromed will expand its value chain and gain direct access to reylon's expertise.   Notifying person: Uwe Perbandt, CEO Viromed Medical AG Contact Viromed: E-Mail:  [email protected] End of Inside Information 03-March-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. View original content: EQS News Language: English Company: Viromed Medical AG Hauptstraße 105 25462 Rellingen Germany E-mail: [email protected] Internet: https://www.viromed-medical-ag.de/ ISIN: DE000A40ZVN7 WKN: A40ZVN Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt, Hamburg, Tradegate BSX EQS News ID: 2284950   End of Announcement EQS News Service 2284950  03-March-2026 CET/CEST

View stock analysis, news, and events for Viromed Medical Ag